Game over as AstraZeneca rejects final $119bn Pfizer bid

AstraZeneca has rejected a final takeover bid of $119bn from Pfizer, marking an end to a month of fevered speculation about the potential merger of the two big pharma groups. "We have rejected Pfizer's final proposal because it is inadequate and would present significant risks for shareholders, while also having serious consequences for the Company, our employees and the life-sciences sector in the UK, Sweden and the US," said AstraZeneca.